Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2022 16:02 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment...